Market Cap 653.88M
Revenue (ttm) 0.00
Net Income (ttm) -266.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,808,700
Avg Vol 3,767,900
Day's Range N/A - N/A
Shares Out 225.48M
Stochastic %K 56%
Beta 1.78
Analysts Strong Sell
Price Target $9.33

Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modi...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 701 7914
Address:
188 East Blaine Street, Suite 400, Seattle, United States
Tradingthefutures
Tradingthefutures Jun. 26 at 10:44 PM
$SANA next step is dilution? If the recent move didn’t move the market, dilution is next unfortunately. Then may be an entry point.
0 · Reply
Bates333
Bates333 Jun. 26 at 3:29 PM
$SANA sold all, I’ll be back
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 26 at 2:36 AM
$SANA Also T1D, especially in children sucks. So dilute away if you got to Harr. Let’s eradicate this BS disease!
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 26 at 2:31 AM
$SANA typed in T1D in twitter… FKN BOOM https://x.com/breakthrought1d/status/1937242845041012817?s=46
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 25 at 11:19 PM
$SANA ppl don’t get confused here, transplanted cells to cure T1D is not novel, SC for pancreatic islets is not novel. Hiding those cells from the immune system is. That was the big trick and we pulled it off successfully. If you must focus on the “cure“ side of things the trials can run shorter because of the nature of the cure and the kill switch that was added. If things go wrong, turn the cure off and voila, nobody has to die!
1 · Reply
Poshfox
Poshfox Jun. 25 at 9:37 PM
$SANA i may be starry eyed & overly optimistic, but im of the inclination that if sc451 works as well as uppsala pt, the fda/nih whoever, steps in and speeds this way up. Like snap approval after p2 w/ post mkt p3. Again assuming it works like it has in the one pt. Big if, but if no sae’s and it’s really a cure, they aren’t going to put it off for yrs. Not this fda. The rub is one pt, can it do the same in 12-20? 50-100? Also think the pps would be @ $5-7 right now if the “as” was an “in”. Like “early in 2026”, not “early as 2026”. That could be end of ‘26! Almost 2 yrs to submit an nda for a cure is ridiculous. This isn’t some cns drug who’s effectiveness depends on holding your head right and squinting one eye to see it. It’s a cure for t1d. A plague on humans documented from the time of the pyramids. Do they really think the fda is gonna nitpick them on the Nda for a cure? Get it in the dam clinic! Putting it off that long is a red flag to some/many. LFG
1 · Reply
Doc_G
Doc_G Jun. 25 at 3:01 AM
$SANA yeah I think imma throw $50 at this one
1 · Reply
Kevin8169
Kevin8169 Jun. 24 at 11:07 PM
$SANA Type 1 diabetes cure is here (Sana has it), will be publicly available in 5-10 years or less. Let that sink in.... How to know with certainty that it's here? => Vertex trial showed stem cell derived islets cure type 1 diabetes. Sana trial shows their tech eliminates need for immunosuppression to enable islets to survive implantation (in Vertex trial, 1 patient of 12 died from immunosuppression, that's a MASSIVE problem that Sana tech solves). Put those 2 facts together and type 1 diabetes cure is inevitable, it's basically here. Sana will make it, NOT Vertex. Curing type 1 diabetes, but dying due to immunosuppressants is a non-starter for Vertex approach. For Sana, just a matter of going through the trials now (Sana has the immune evasive stem cell derived islets ready to go). The cure is already proven essentially. Sana massively undervalued at $660M. Investors will support Sana along the way to unlocking this massive market opportunity.
3 · Reply
View2021
View2021 Jun. 24 at 8:22 PM
$SANA bought a total of 50k over the day today Going to $12
0 · Reply
BriOnH
BriOnH Jun. 24 at 6:30 PM
$SANA I don't usually TA this ticker because I am in it for the long run, but if I was trading it, which again, I am not, it has a possible cup and handle forming for potential breakout on the daily. C&H breakout rate = roughly 65%.
3 · Reply
Latest News on SANA
Two Biotech Stocks Poised For Big Moves On Monday

Jun 23, 2025, 7:39 AM EDT - 3 days ago

Two Biotech Stocks Poised For Big Moves On Monday

LCTX


Sana Biotechnology to Present at June 2025 Investor Conferences

May 28, 2025, 4:05 PM EDT - 4 weeks ago

Sana Biotechnology to Present at June 2025 Investor Conferences


Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Mar 24, 2025, 11:45 PM EDT - 3 months ago

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421


This Biotech Stock Just Soared 240%. Why It Can Go Higher.

Jan 8, 2025, 7:25 AM EST - 6 months ago

This Biotech Stock Just Soared 240%. Why It Can Go Higher.


Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Dec 4, 2024, 3:36 PM EST - 7 months ago

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus


Sana Biotechnology: The Story Becomes Murkier

Nov 19, 2024, 5:31 PM EST - 7 months ago

Sana Biotechnology: The Story Becomes Murkier


Tradingthefutures
Tradingthefutures Jun. 26 at 10:44 PM
$SANA next step is dilution? If the recent move didn’t move the market, dilution is next unfortunately. Then may be an entry point.
0 · Reply
Bates333
Bates333 Jun. 26 at 3:29 PM
$SANA sold all, I’ll be back
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 26 at 2:36 AM
$SANA Also T1D, especially in children sucks. So dilute away if you got to Harr. Let’s eradicate this BS disease!
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 26 at 2:31 AM
$SANA typed in T1D in twitter… FKN BOOM https://x.com/breakthrought1d/status/1937242845041012817?s=46
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 25 at 11:19 PM
$SANA ppl don’t get confused here, transplanted cells to cure T1D is not novel, SC for pancreatic islets is not novel. Hiding those cells from the immune system is. That was the big trick and we pulled it off successfully. If you must focus on the “cure“ side of things the trials can run shorter because of the nature of the cure and the kill switch that was added. If things go wrong, turn the cure off and voila, nobody has to die!
1 · Reply
Poshfox
Poshfox Jun. 25 at 9:37 PM
$SANA i may be starry eyed & overly optimistic, but im of the inclination that if sc451 works as well as uppsala pt, the fda/nih whoever, steps in and speeds this way up. Like snap approval after p2 w/ post mkt p3. Again assuming it works like it has in the one pt. Big if, but if no sae’s and it’s really a cure, they aren’t going to put it off for yrs. Not this fda. The rub is one pt, can it do the same in 12-20? 50-100? Also think the pps would be @ $5-7 right now if the “as” was an “in”. Like “early in 2026”, not “early as 2026”. That could be end of ‘26! Almost 2 yrs to submit an nda for a cure is ridiculous. This isn’t some cns drug who’s effectiveness depends on holding your head right and squinting one eye to see it. It’s a cure for t1d. A plague on humans documented from the time of the pyramids. Do they really think the fda is gonna nitpick them on the Nda for a cure? Get it in the dam clinic! Putting it off that long is a red flag to some/many. LFG
1 · Reply
Doc_G
Doc_G Jun. 25 at 3:01 AM
$SANA yeah I think imma throw $50 at this one
1 · Reply
Kevin8169
Kevin8169 Jun. 24 at 11:07 PM
$SANA Type 1 diabetes cure is here (Sana has it), will be publicly available in 5-10 years or less. Let that sink in.... How to know with certainty that it's here? => Vertex trial showed stem cell derived islets cure type 1 diabetes. Sana trial shows their tech eliminates need for immunosuppression to enable islets to survive implantation (in Vertex trial, 1 patient of 12 died from immunosuppression, that's a MASSIVE problem that Sana tech solves). Put those 2 facts together and type 1 diabetes cure is inevitable, it's basically here. Sana will make it, NOT Vertex. Curing type 1 diabetes, but dying due to immunosuppressants is a non-starter for Vertex approach. For Sana, just a matter of going through the trials now (Sana has the immune evasive stem cell derived islets ready to go). The cure is already proven essentially. Sana massively undervalued at $660M. Investors will support Sana along the way to unlocking this massive market opportunity.
3 · Reply
View2021
View2021 Jun. 24 at 8:22 PM
$SANA bought a total of 50k over the day today Going to $12
0 · Reply
BriOnH
BriOnH Jun. 24 at 6:30 PM
$SANA I don't usually TA this ticker because I am in it for the long run, but if I was trading it, which again, I am not, it has a possible cup and handle forming for potential breakout on the daily. C&H breakout rate = roughly 65%.
3 · Reply
CelestialIronMan
CelestialIronMan Jun. 24 at 6:10 PM
$SANA so odd seeing the options gap between $2.5 and $5 and all the resistance at $3… what happened in that pocket?
2 · Reply
CelestialIronMan
CelestialIronMan Jun. 24 at 6:09 PM
$SANA I don’t think anything is more exciting than biotech investing! To get here this early…
0 · Reply
Kevin8169
Kevin8169 Jun. 24 at 5:48 PM
$SANA i'm willing to die on the hill that a type 1 diabetes cure is worth more than $660M. Ask yourself, what would Sana get acquired for? I guarantee you it's way more than that.
5 · Reply
AdrianDittmann
AdrianDittmann Jun. 24 at 5:29 PM
$SANA $TNDM $PODD $MDT $SPY Have you seen Sana Biotech's new treatment, they were able to transfer modified islet cells that can evade the immune system. I think we are finally there! What do you guys think?
3 · Reply
cta7978
cta7978 Jun. 24 at 5:16 PM
$SANA OK, let's see if we finally get a close above $3.00 or another algo selloff.
0 · Reply
FIRE_soon
FIRE_soon Jun. 24 at 5:16 PM
$SANA is a great FIRE opportunity from here. 🚀🚀🚀
0 · Reply
peej0345
peej0345 Jun. 24 at 5:06 PM
0 · Reply
Kevin8169
Kevin8169 Jun. 24 at 4:12 PM
$SANA shorts were unable to knock the stock down
0 · Reply
rubraquercus
rubraquercus Jun. 24 at 3:24 PM
$SANA A global partner for T1d is the next step and a big fat cash signing bonus so they run internally with Lupus and a few others...
1 · Reply
prismmarketview
prismmarketview Jun. 24 at 2:16 PM
$SANA https://prismmarketview.com/sana-advances-toward-a-functional-cure-for-type-1-diabetes-with-six-month-data-from-first-in-human-study/
0 · Reply
DrunkStockTrader69
DrunkStockTrader69 Jun. 24 at 1:01 PM
$SANA $SANA T1 Diabetes cure might truly be possible not only that the application may be used for other treatments On June 23, 2025, Sana reported that in a first-in human Type 1 diabetes trial, pancreatic islet cells engineered with its Hypoimmune (HIP) platform survived and produced insulin for six months without immunosuppression MRI scans and sustained C peptide levels during mixed meal tolerance tests confirmed these cells remain alive and functional Analysts noted this is likely the first allogeneic islet cell transplant without immune suppression in an immune competent patient a potential game changer H.C. Wainwright maintained a Buy rating with an $11 price target, citing the 6-month data and upcoming follow-ups https://www.globenewswire.com/news-release/2025/06/23/3103540/0/en/Sana-Biotechnology-Announces-Positive-Six-Month-Clinical-Results-from-Type-1-Diabetes-Study-of-Islet-Cell-Transplantation-Without-Immunosuppression.html
0 · Reply
Olivia_Love
Olivia_Love Jun. 24 at 1:00 PM
$SANA Part-2 4. Oncology – SC262 (CD22 CAR T) • Phase I VIVID trial for B‑cell malignancies (post-CD19 CAR T failures) continues enrolling, with results expected in 2025 . 5. In vivo CAR T – SG299 (fusogen platform) • Preclinical data in non-human primates showed deep B-cell depletion without chemotherapy . • Sana aims to file an IND in 2026 . ⸻ ⚙️ Strategic Refocus & Financial Positioning • The company has pivoted away from oncology (SC291 in cancer) and CNS (SC379) to preserve cash, focusing on diabetes and autoimmune programs . • Cash runway extends into 2026, giving breathing room to advance key candidates . • Management signals additional investor data releases, IND filings, and scientific presentations throughout the remainder of 2025.
0 · Reply